Jones Financial Companies
MRNA icon

Jones Financial Companies’s Moderna MRNA Stock Holding History

Jones Financial Companies’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.37M Buy
50,019
+7,184
+17% +$372K ﹤0.01% 1362
2026
Q1 		$2.12M Buy
42,835
+3,084
+8% +$144K ﹤0.01% 1402
2025
Q4 		$1.17M Sell
39,751
-5,497
-12% -$149K ﹤0.01% 1166
2025
Q3 		$1.11M Buy
45,248
+306
+0.7% +$8.54K ﹤0.01% 1095
2025
Q2 		$1.22M Buy
44,942
+14,246
+46% +$375K ﹤0.01% 933
2025
Q1 		$955K Buy
30,696
+15,855
+107% +$563K ﹤0.01% 881
2024
Q4 		$617K Buy
14,841
+7,883
+113% +$377K ﹤0.01% 912
2024
Q3 		$457K Buy
6,958
+2,666
+62% +$245K ﹤0.01% 852
2024
Q2 		$510K Buy
4,292
+3,352
+357% +$424K ﹤0.01% 564
2024
Q1 		$100K Buy
+940
New +$94.8K ﹤0.01% 590
2023
Q2 		– Sell
-150
Closed -$23K – 570
2023
Q1 		$23K Buy
150
+112
+295% +$18.5K ﹤0.01% 410
2022
Q4 		$7K Buy
+38
New +$6.21K ﹤0.01% 511

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Jones Financial Companies's MRNA Position: Q2 2026 in Review

Jones Financial Companies increased its Moderna (MRNA) stake by 17% in Q2 2026, buying an estimated $372K and bringing the position to 50,019 shares worth $3.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1362.

Jones Financial Companies first reported a position in MRNA in Q4 2022 and has held it in 12 quarters since. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Jones Financial Companies held 50,019 shares of Moderna worth $3.37M as of Q2 2026.
  • Jones Financial Companies bought 7,184 Moderna shares in Q2 2026, an estimated $372K.
  • Moderna made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1362 holding.
  • Jones Financial Companies first reported a position in Moderna in Q4 2022 and has held it in 12 quarters since.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.